Visceral Cancer Pain

Overview

Introduction

• Visceral cancer pain is a complex and debilitating symptom arising from malignancies affecting thoracic, abdominal, or pelvic organs. It is typically diffuse, poorly localized, and associated with pronounced autonomic and emotional distress.
• Among patients with advanced cancer, pain affects 60–80%, and visceral pain accounts for many of the most severe cases.¹
• Recent progress in understanding the neurobiology of visceral nociception1,2 and innovations in opioid-sparing pharmacologic and interventional strategies have expanded the anesthesiologist’s role in comprehensive cancer pain management.

Mechanisms of Visceral Cancer Pain

• The mechanisms underlying visceral cancer pain are multifactorial and include mechanical, ischemic, inflammatory, neuropathic, and central sensitization processes (Figure 1).
• Mechanical pain results from organ distension, capsular stretch, or luminal obstruction.¹
• Ischemic pain arises from tumor infiltration or compression of visceral vasculature, leading to acidosis and metabolic distress.¹
• Inflammatory mechanisms involve cytokines, including IL-1β, IL-6, TNF-α, prostaglandins, and serotonin, which sensitize visceral afferents and amplify nociceptive transmission.^1,3
• Neuropathic components emerge when tumors invade sympathetic or splanchnic nerves, producing persistent hyperalgesia and allodynia.^1,2 Sustained afferent input triggers central sensitization mediated by N-methyl D-aspartate (NMDA) receptor activation, c-fos expression, and dorsal-horn hyperexcitability.²

Pathophysiology of Referred and Diffuse Pain

• Visceral pain is often referred to somatic structures due to the convergence of visceral and somatic afferents on shared dorsal‐horn neurons.1 This convergence-projection mechanism explains why hepatic or pancreatic pain may be perceived in the back or shoulder.
• Visceral afferents travel through sympathetic (splanchnic) and parasympathetic (vagal and pelvic) pathways to laminae I, V, VII, and X of the spinal cord.^1,2
• Ascending pathways, including the spinothalamic and spinoreticular tracts, transmit sensory and affective components to the thalamus, limbic system, and cortex.

Clinical Features and Current Treatment Strategies

Clinical Features and Assessment

• Visceral cancer pain is typically characterized as deep, aching, pressure-like, and poorly localized. Patients may report nausea, diaphoresis, bloating, or altered bowel habits. Tools such as the Edmonton Symptom Assessment Scale and Brief Pain Inventory quantify severity and functional impact.
• Differentiating visceral cancer pain from therapy‐related pain syndromes, such as post-thoracotomy pain, postmastectomy pain, radiation‐induced fibrosis, or chemotherapy-related neuropathy, is essential for accurate management.

Pharmacologic Management

• Pharmacologic therapy remains foundational and follows World Health Organization principles for cancer pain management.⁴
• Non-opioids, including nonsteroidal anti-inflammatory drugs and acetaminophen, are used for mild inflammatory pain.
• Opioids, most commonly morphine, remain the standard for moderate to severe pain, though rotation to hydromorphone, oxycodone, fentanyl, or methadone may be necessary.⁴
• Adjuvant medications such as gabapentinoids, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and corticosteroids target inflammatory and neuropathic mechanisms.^1,3
• Please see the OA summary on the WHO Analgesic Ladder for more details. Link
• Refractory pain may respond to ketamine or lidocaine infusions, which modulate NMDA receptors and sodium channels, respectively.
• Emerging treatments, including cannabinoids and P2X₃ antagonists, reflect ongoing mechanistic advances.³

Regional and Interventional Approaches

• Interventional strategies are critical for opioid‐refractory visceral cancer pain.
• Neurolysis of the celiac plexus has been shown in a Cochrane review to reduce pain severity in upper abdominal malignancies.⁵
• Superior hypogastric plexus block is effective for pelvic malignancies, while ganglion impar block targets rectal and perineal pain.
• Intrathecal drug delivery systems allow continuous administration of agents such as morphine, clonidine, or ziconotide with reduced systemic effects; their use in cancer pain is supported by consensus guidelines.⁶
• Neuromodulation, including spinal cord stimulation and dorsal root ganglion stimulation, is increasingly being explored for complex neuropathic‐dominant cancer pain.^2,3

Multimodal and Integrative Approaches

• Optimal management integrates pharmacologic, interventional, psychological, and supportive therapies. Anesthesiologists collaborate closely with palliative care teams, physical therapists, and mental health professionals to address the full biopsychosocial burden of visceral cancer pain.
• Cognitive‐behavioral therapy, mindfulness‐based interventions, and structured coping strategies support opioid reduction and improve quality of life.⁴

Future Directions

• Future directions in visceral cancer pain research focus on precision pain medicine driven by molecular and neurophysiologic insights.
• Sodium channel modulators (NaV1.7, NaV1.8), transient receptor potential vanilloid 1 antagonists, and cytokine‐targeted therapies represent promising avenues for treatment.³
• Advanced neuroimaging techniques, such as functional magnetic resonance imaging and positron emission tomography, may facilitate pain phenotyping and individualized treatment.²
• Artificial intelligence‐based models are being developed to predict analgesic response and identify high-risk patients earlier in their disease course. Integration of anesthesiology into oncologic care pathways continues to expand.⁴